Davies M, Faerch L, Jeppesen OK, Pakseresht A, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021 Mar 2. pii: S0140-6736(21)00213.
PMID: 33667417